[尼尔塞维玛的有效性防止婴儿因呼吸道综合体病毒支气管炎住院]
R Rodríguez-Fernández1, F González-Martínez, I Ojeda Velázquez
1Rosa Rodriguez-Fernández. Sección de Pediatría Interna Hospitalaria. Servicio de Pediatría. Hospital Gregorio Marañón. Calle O'Donnell 50, 28007, Madrid, Spain. rrfernandez@salud.madrid.org.
概括
在6个月以下的婴儿中,nirsevimab显著减少了呼吸道同胞性病毒 (RSV) 的住院病例. 这种新的抗体在预防RSV支气管炎住院治疗方面具有85%的有效性,这表明它对婴儿保健有重大影响.
科学领域:
- 儿科 儿科 儿科
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 呼吸道综合体病毒 (RSV) 支气管炎是婴儿住院的主要原因.
- 长半衰期单克隆抗体Nirsevimab现在可以用于婴儿的RSV预防.
研究的目的:
- 评估Nirsevimab实施对婴儿RSV入院的影响.
- 评估Nirsevimab在现实世界医院环境中的有效性.
主要方法:
- 采用了观察性,回顾性和分析性研究设计.
- 接受支气管炎治疗的六个月以下婴儿在Nirsevimab前后期间 (2015年9月至2023年9月与2023年10月至12月) 进行了分析.
- 使用双阴性试验 (1-Odds比率) × 100计算有效性.
主要成果:
- 与之前的季节相比,在Nirsevimab时代,RSV支气管炎的入院率从48%降至4.3% (p<0.01).
- 尼尔塞维马布在预防6个月以下婴儿RSV入院方面表现出85%的有效性 (95%CI:32-97%).
- 期间之间没有观察到支气管炎严重程度的显著差异.
结论:
- 尼尔西维玛布的实施显著减少了婴儿RSV支气管炎入院的数量.
- 该研究强调了Nirsevimab对RSV导致的婴儿住院治疗的重大影响.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Acute Respiratory Failure-II
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...


